Loading people...
Garri Zmudze is a Miami, Florida-based venture capitalist currently serving as General Partner at LongeVC and Co-Founder of the Longevity Science Foundation. Prior to establishing LongeVC, he co-founded Longenesis, an early-stage medical technology startup focused on bridging healthcare and biotechnology for accelerated drug discovery. As an active angel investor in emerging science-intensive ventures, his portfolio includes artificial intelligence drug discovery company Insilico Medicine and pet genetics startup Basepaws, which was acquired by Zoetis in 2022. In late 2021, he helped launch the Swiss non-profit Longevity Science Foundation, an organization that aims to distribute $1 billion in funding toward aging research over a decade. Holding a bachelor's degree in business administration from RISEBA University of Applied Sciences, Zmudze maintains a primary investment focus on biotechnology, personalized medicine, and deep tech solutions designed to extend human healthspan.
Garri Zmudze stands as a pivotal figure in the venture capital landscape, serving as a General Partner at LongeVC. In this capacity, he is instrumental in shaping the firm's investment strategy, driving deal sourcing, and providing strategic guidance to a portfolio of groundbreaking companies. LongeVC, under his leadership, is committed to identifying and backing early-stage ventures that are at the forefront of innovation in longevity, biotechnology, and health technology.
His investment focus is sharply honed on disruptive technologies and scientific breakthroughs that promise to extend healthy human lifespan and improve quality of life. This includes a wide array of areas such as novel therapeutics, advanced diagnostics, preventative medicine, personalized healthcare solutions, and age-reversal technologies. Garri's keen eye for potential allows LongeVC to invest in companies that are not only scientifically sound but also possess strong market potential and the ability to create significant societal impact.
Garri Zmudze's career background is marked by a deep understanding of finance, strategic development, and the intricate dynamics of the healthcare and life sciences industries. Prior to his role at LongeVC, he accumulated extensive experience in various capacities that honed his expertise in identifying high-growth opportunities and navigating complex investment landscapes. This foundation has equipped him with a unique perspective, enabling him to effectively evaluate the scientific rigor and commercial viability of nascent technologies in the longevity space. His entrepreneurial spirit and vision have been key drivers in establishing LongeVC as a prominent player in this specialized and rapidly evolving sector.
While specific individual investments are often part of a broader fund strategy, Garri has been instrumental in building LongeVC's diverse portfolio, which includes companies developing cutting-edge solutions from gene therapies to AI-powered diagnostics. His work ensures that LongeVC supports founders who are pushing the boundaries of what is possible in human health. He is deeply involved in fostering the growth of these companies, offering not just capital but also strategic mentorship and access to a vast network of industry experts. Garri Zmudze's dedication to advancing the field of longevity and health technology underscores his commitment to a future where extended health and vitality are accessible to all.
Garri Zmudze is a General Partner at LongeVC, a venture capital firm specializing in early-stage investments in longevity, biotech, and health technology.
Garri Zmudze invests in early-stage companies focused on longevity, biotechnology, and health technology, seeking disruptive innovations that aim to extend healthy human lifespan and improve health outcomes.
Garri Zmudze works as a General Partner at LongeVC, a venture capital firm dedicated to the longevity and health tech sectors.
